No Data
No Data
Kexing Biopharm Obtained Clinical Trial Approval for Its Self-developed Class I Innovative Drug--Long-acting Growth Hormone
On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently...
Kexing Biopharm's Unit to Trial Growth Deficiency Drug
Kexing Biopharm's (SHA:688136) unit, Shenzhen Kexing Bioproducts, will conduct clinical trials on GB08 injection after obtaining approval from China's National Medical Products Administration, the com
Kexon Pharmaceuticals (688136.SH): Proposed 3.786 million restricted stock incentive plan
Ge Longhui, May 24, 丨 Kexon Pharmaceuticals (688136.SH) announced the 2024 restricted stock incentive plan. The number of restricted shares to be granted under this incentive plan is 3.786 million shares, accounting for 1.90% of the company's total share capital of 19.919.865 million shares when the draft incentive plan was announced. This incentive plan is intended to grant incentives to a total of 147 people. The grant price of restricted shares under this incentive plan is 12 yuan/share.
Kexon Pharmaceuticals (688136.SH): Obtained GB08 Notice of Approval for Clinical Trials of Injectable Drugs
Gelonghui Pharmaceutical (688136.SH) announced on May 24, that its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the State Drug Administration approved Shenzhen Kexing to carry out clinical trials of “GB08 Injection”. GB08 injection is the company's first self-developed Class I innovative drug. It is an Fc fusion protein long-lasting growth hormone independently developed by the company according to clinical patient needs and based on growth hormone deficiency in children.
Kexing Pharmaceuticals (688136.SH): A total cost of 31.12 million yuan to buy back 0.94% of shares
Gelonghui, May 21丨Kexon Pharmaceuticals (688136.SH) announced that as of the disclosure date of this announcement, the company's share repurchase period has expired, the company's cumulative repurchase amount through centralized bidding transactions has reached the lower limit of the repurchase amount, and the implementation of this share repurchase plan has been completed. The company has repurchased 1,880,572 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 0.94% of the company's total share capital. The highest price of the repurchase transaction was 19.95 yuan/share, the lowest price was 14.30 yuan/share, the average repurchase price was 16.55 yuan/share, and the total amount of capital paid
Kexing Biopharm Obtiene La Certificación GMP De La UE Para Paclitaxel Inyectable (Unido a Albúmina)
SHENZHEN, China, 10 de mayo de 2024 /PRNewswire/ -- En la tarde del 5 de mayo, Kexing Biopharm (código bursátil: 688136) anunció que había obtenido un "Certificado de Conformidad GMP de un Fabric
No Data